24 results on '"Parente P."'
Search Results
2. 165P Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
3. 160MO Concomitant medication (conmed) interactions with novel hormonal agents (NHAs) in metastatic castration resistant prostate cancer (mCRPC)
4. Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors
5. 934P Harnessing artificial intelligence on real-world data to predict recurrence in head and neck squamous cell carcinoma patients: The HNC-TACTIC study
6. 225P Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
7. 226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
8. Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC)
9. Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients
10. Comparison of first-line treatment options for metastatic castrate resistant prostate cancer: A retrospective cohort study
11. Correlation of a whole blood RNA assay detecting AR-v7 expression with PSA response in patients with metastatic castration-resistant prostate cancer (mCRPC)
12. Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
13. PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
14. 220P - Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC)
15. 1256P - Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients
16. 266P - Correlation of a whole blood RNA assay detecting AR-v7 expression with PSA response in patients with metastatic castration-resistant prostate cancer (mCRPC)
17. 263O - Comparison of first-line treatment options for metastatic castrate resistant prostate cancer: A retrospective cohort study
18. 810P - Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
19. Impact of Tumour Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer (Mcrc)
20. 722PD - PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
21. Cabazitaxel (CBZ) + Prednisone (P; CBZP) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel (D): Interim Results from Compassionate-Use Programme (CUP) and Early-Access Programme (EAP)
22. 513P - Impact of Tumour Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer (Mcrc)
23. 931P - Cabazitaxel (CBZ) + Prednisone (P; CBZP) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel (D): Interim Results from Compassionate-Use Programme (CUP) and Early-Access Programme (EAP)
24. 366P Clinicopathological predictors of favourable response to docetaxel in patients with metastatic castration-resistant prostate cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.